Dive Brief:
- Diabetes tech firms Senseonics and Beta Bionics launched an integration this week of their glucose sensors and insulin pumps.
- Senseonics makes a continuous glucose monitor that can be implanted for up to a year, called Eversense 365. That device is now compatible with Beta Bionics’ iLet Bionic Pancreas automated insulin delivery system.
- The integration follows a partnership that the two companies struck in September. In the future, they plan to also pair Senseonics’ one-year CGM with Beta Bionics’ new tubeless patch pump, called Mint.
Dive Insight:
The integration is intended to make it easier for people to manage their diabetes and expand their device choices.
Senseonics’ implantable design, with fewer sensor changes and high accuracy even at low glucose levels, makes it well suited for automated insulin delivery, the companies said in a statement. Meanwhile, Beta Bionics’ iLet device is intended to minimize the need for carb counting or manual correction boluses. Beta Bionics Chief Commercial Officer Mark Hopman said in a statement that the partnership should help reduce the “constant work and decision-making that can come with managing diabetes.”
Currently, Senseonics’ Eversense 365 CGM is integrated with one other pump, Sequel Med Tech’s twist automated insulin delivery system. In an earnings call earlier this month, Senseonics Chief Commercial Officer Brian Hansen said the Sequel partnership has benefited both companies almost one year later. The lack of pump compatibility was a reason people discontinued using Senseonics sensors, so adding a second option “is very exciting for us.”
Beta Bionics’ iLet pump, for its part, is also compatible with sensors made by Abbott and Dexcom. The company received FDA clearance for its first insulin patch pump, Mint, in September. Beta Bionics is planning a full U.S. launch of the device for the first quarter of 2027.